Crude Oil Moves Higher; US Factory Orders Rise In July
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
Stocks · News reference
CDT Equity Reports $23M Market Value And No Remaining Nasdaq Deficiencies
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CDT Equity shares are trading lower after the company announced that, following share issuances and warrant exercises, it had 13.7 million shares outstanding, valuing the firm at about $23 million despite resolving Nasdaq deficiencies.
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity Inc. (Nasdaq: CDT) announced 13.7 million shares outstanding as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company confirmed it no longer has outstanding deficiencies with Nasdaq following recent share issuances and corporate actions. CDT, a data-driven biopharmaceutical development company, reported stockholders' equity of approximately $103 million as of June 30, 2026.